ArticleAsian Pacific journal of cancer prevention : APJCP2019
The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Polydopamine Nanoparticle-Based Combined Chemotherapy and Photothermal Therapy for the Treatment of Liver Cancer.ACS applied materials & interfaces · 2024Article
- Metal nanoparticles as a potential technique for the diagnosis and treatment of gastrointestinal cancer: a comprehensive review.Cancer cell international · 2023Review
- Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, "Naked" Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells.International journal of molecular sciences · 2022Article
- Multifunctional Gold Nanoparticles in Cancer Diagnosis and Treatment.International journal of nanomedicine · 2022Review
- Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy.Asian journal of pharmaceutical sciences · 2021Review
- Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gold nanoparticles are the most promising candidate in cancer treatment due to their physiochemical properties<br /> and increased use in photothermal therapy (PTT). In the present study, spherical gold nanoparticles (AuNPs) were<br /> synthesized using citrate reduction method. The particles were then characterized using UV-VIS spectroscopy and<br /> transmission electron microscope. A hepatocellular carcinoma cell line (HepG2) was incubated with sorafenib and/or<br /> non-irradiated or laser-irradiated AuNPs for 48 hrs. The cytotoxic effect of different treatment modalities was determined<br /> using MTT assay. Furthermore, apoptosis was determined by flow cytometry using annexin V/propidium iodide, as<br /> well as estimating the level of caspases. Results showed that AuNPs and sorafenib reduced HepG2 cell viability, and<br /> the cytotoxicity was associated with increased release of LDH in the culture medium. The recorded cytotoxicity was<br /> attributed to enhanced apoptosis as revealed by increased cellular caspases (3, 8 and 9), that was further confirmed by<br /> flow cytometry. The most notable cytotoxic effect was recorded when combining sorafenib with laser-irradiated AuNPs.<br /> In conclusion, a synergistic cytotoxic effect was observed between sorafenib and laser-irradiated AuNPs against the<br /> growth of HepG2, suggesting the potential substitution of large toxic doses of sorafenib by lower doses in combination<br /> with photothermal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.